MARKSANS

- Marksans Pharma Ltd. to acquire 100% share capital of Germany-based pharmaceutical company ABCnow GmbH for a cash consideration of €892,384.- The acquisition aims to expand Marksans' presence in European markets and strengthen its forward-integration strategy through direct market access.- ABCnow GmbH had a turnover of €227,233.69 as on December 31, 2025.- The acquisition is expected to be completed by July 31, 2026.

- Board recommended a final dividend of ₹0.90 (90%) per equity share for FY2026. - Record Date for determining eligibility for the dividend is August 20, 2026. - The 34th Annual General Meeting (AGM) will be held on August 27, 2026. - The final dividend, if approved, will be paid on or after September 10, 2026.

- The 34th Annual General Meeting (AGM) is scheduled for Thursday, August 27, 2026, at 11:00 a.m. - The Record Date for determining eligibility for the final dividend for FY26 is Thursday, August 20, 2026. - The Board recommended a final dividend of ₹0.90 (90%) per equity share for FY26, subject to AGM approval. - If approved, the dividend will be paid on or after Thursday, September 10, 2026.

- Board recommended a final dividend of ₹0.90 (90%) per equity share for the financial year ended March 31, 2026. - The Record Date for determining eligibility for the dividend is August 20, 2026. - The 34th Annual General Meeting (AGM) will be held on August 27, 2026. - If approved, the dividend will be paid on or after September 10, 2026.

- 34th Annual General Meeting (AGM) on August 27, 2026, at 11:00 a.m. - Record Date for FY2026 final dividend of ₹0.90/- (90%) per share is August 20, 2026. - Dividend payment on or after September 10, 2026, subject to AGM approval.

- Board meeting held on July 03, 2026. - 34th AGM scheduled for August 27, 2026. - Record Date for final dividend of ₹0.90/share for FY26 is August 20, 2026. - Dividend payment on or after September 10, 2026, subject to AGM approval.

- Trading window for designated persons and their immediate relatives will remain closed from July 01, 2026. - Closure is until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026.

- Consolidated Revenue ₹8,561.14Mn vs ₹7,084.57Mn (▲21% YoY) - EBITDA ₹1,954.21Mn vs ₹1,269.35Mn (▲54% YoY) - PAT ₹1,490.32Mn vs ₹907.26Mn (▲64% YoY) - EBITDA Margin 23% vs 18% (▲491bps) - Board recommended a final dividend of ₹0.90 per equity share (90%) for FY 2025-26.

- Marksans Pharma Ltd. launched "Saksham Niveshak" campaign to help shareholders claim unclaimed dividends from FY2018-19 onwards. - The campaign also aims to facilitate KYC updates and prevent transfer of funds to IEPF. - Shareholders can contact RTA or Company Secretary. - The deadline for claims/documents is July 08, 2026.

- Marksans Pharma Ltd. has completed the acquisition of 100% share capital of QliniQ B.V., based in the Netherlands.

- India Ratings and Research (Fitch Group) revised the outlook for Marksans Pharma Ltd.'s ₹195.75 Cr bank loan facilities to 'Positive' from 'Stable'. - The ratings of IND AA- / Positive / IND A1+ were affirmed.

- Investor Conference Schedule - Conference Date: June 10, 2026 - Conference Time: 03:00 PM IST

- Marksans Pharma reported highest ever profitability in FY26, crossing INR3,000 crores in net income for the first time. - Q4 FY26 Operating Revenue grew 20.8% YoY to INR856 crores. EBITDA increased 54% YoY to INR195 crores, with margin at 22.8%. PAT rose 64.3% YoY to INR149 crores. - FY26 Operating Revenue grew 12.5% YoY to INR2,951 crores. EBITDA was INR601 crores (margin 20.4%), and PAT was INR420 crores. - The Board recommended a final dividend of INR0.90 per equity share for FY26. - The company remains debt-free with a cash balance of INR990 crores as of March 31, 2026. - **Guidance & Outlook:** - Targets INR4,000 crores revenue within the next 2 years (FY28). - Expects 15-20% top-line growth and EBITDA margins to remain in the 20-21% range for FY27. - Anticipates M&A activity in 2027, with two targets in active dialogue. - Plans to file over 200 new products in the U.K. market over the next 4 years. - Forecasts $100 million revenue from Australia/New Zealand within the next 3 years. - Mentions potential for raw material cost inflation in Q1 FY27 but expects to manage it with inventory and forex benefits.

- Marksans Pharma Ltd. launched a "Saksham Niveshak" 100-day campaign to help shareholders claim unclaimed dividends from FY2018-19 onwards. - The campaign also facilitates updating KYC, contact, and bank details. - Shareholders should submit claims before June 17, 2026.

Marksans Pharma Ltd. announced the acquisition of 100% share capital of Netherlands-based QliniQ B.V. for a cash consideration of €7.5 million. QliniQ B.V., a profitable, debt-free pharmaceutical company, reported a FY2025 revenue of €9.35 million and net profit of €1.01 million, with a 41% CAGR from FY2023-FY2025. This strategic acquisition will strengthen Marksans' presence in European markets by providing direct access to the Netherlands market and enhancing commercialization capabilities. The acquisition is expected to complete by June 15, 2026.

Marksans Pharma Ltd. announced on May 27, 2026, that it has uploaded the audio recording of its investor/analyst conference call on the Q4 FY26 financial results to its company website, as per Regulation 30 of SEBI LODR Regulations, 2015.

Consolidated Revenue ₹856.1 Cr vs ₹708.5 Cr (▲20.8% YoY), EBITDA ₹195.4 Cr vs ₹126.9 Cr (▲54.0% YoY), PAT ₹149.0 Cr vs ₹90.7 Cr (▲64.3% YoY). EBITDA Margin 22.8% vs 17.9% (▲490 bps).

Marksans Pharma Ltd. announced that its Board of Directors approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The Statutory Auditors have issued an unmodified opinion on these results. Additionally, the Board recommended a final dividend of Rs. 0.90 per equity share (90%) for the financial year 2025-26, subject to shareholder approval at the upcoming AGM.

Consolidated Revenue ₹856.11 Cr vs ₹708.46 Cr (▲20.84% YoY), EBITDA ₹195.42 Cr vs ₹126.94 Cr (▲53.95% YoY), PAT ₹149.03 Cr vs ₹90.73 Cr (▲64.26% YoY). EBITDA Margin 22.83% vs 17.92% (▲491bps). The Board also recommended a final dividend of ₹0.90 per equity share (90%) for FY2025-26.

Marksans Pharma Ltd. announced the grant of 3,00,000 (Three Lakh) stock options to eligible employees under the Marksans Employees Stock Option Scheme 2024 on May 25, 2026. The options have an exercise price of Rs. 10/- per stock option, a vesting period of one year, and an exercise period of two years from the date of grant for vested options.

Marksans Pharma Ltd. announced an earnings conference call for analysts and investors on Wednesday, May 27, 2026, at 04:30 PM (IST). The call is scheduled to discuss the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. Management speakers will include Mr. Mark Saldanha (CMD) and Mr. Jitendra Sharma (CFO).